Company intelligence / Profile preview

PolygenRx

Newcastle, New South Wales, Australiapolygenrx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PolygenRx has developed a proprietary genetics-based precision medicine platform designed to match patients with optimal therapies based on their unique genetic risk profiles. The company aims to improve drug discovery success rates and enable targeted treatment for chronic and complex disorders. No clinical results are reported yet.

Therapeutic areas: OtherImmunology
Modalities: Small moleculesPotentially biologics or other drug classes
Industry: Drug Discovery Services

Drug pipeline

6 assets

palbociclib

Pre-clinical

Indications: Type 2 diabetes

5 more assets in the full pipeline.

Request access →

Partnerships

Establishing collaborations with commercial partners for companion diagnostics and furthering drug development efforts—specific partners not named.

Beyond the preview

Go deeper on PolygenRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolygenRx.

Explore the full profile